INSIGHT MOLECULAR DIAGNOSTIC (IMDX) Stock Price, Forecast & Analysis
NASDAQ:IMDX • US68235C2061
IMDX Key Statistics, Chart & Performance
The current stock price of IMDX is 5.72 USD. In the past month the price decreased by -17.59%.
IMDX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IMDX.
IMDX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IMDX. IMDX may be in some trouble as it scores bad on both profitability and health.
IMDX Financial Highlights
Over the last trailing twelve months IMDX reported a non-GAAP Earnings per Share(EPS) of -2.83. The EPS increased by 38.34% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -138.33% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IMDX Forecast & Estimates
10 analysts have analysed IMDX and the average price target is 7.14 USD. This implies a price increase of 24.83% is expected in the next year compared to the current price of 5.72.
For the next year, analysts expect an EPS growth of 73.46% and a revenue growth 545.1% for IMDX
IMDX Ownership
IMDX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.65 | 397.113B | ||
| AMGN | AMGEN INC | 16.89 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.15 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.53 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.22 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.31 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IMDX
Company Profile
Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
Company Info
INSIGHT MOLECULAR DIAGNOSTIC
2 International Plaza Dr., Suite 510
Nashville TENNESSEE US
Employees: 46
Phone: 19494097600
INSIGHT MOLECULAR DIAGNOSTIC / IMDX FAQ
What does INSIGHT MOLECULAR DIAGNOSTIC do?
Insight Molecular Diagnostics, Inc. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. The company is headquartered in Nashville, Tennessee and currently employs 46 full-time employees. The company went IPO on 2015-12-30. The firm's technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company is in the process of rebranding its VitaGraft assay (also known as VitaGraft Kidney), which is a lab developed test, under the name GraftAssureCore. The firm's transplant products include GraftAssureCore, GraftAssureDx, GraftAssureIQ. Its oncology products include DetermaCNI, DetermaIO, and OncoTIME. GraftAssureCore is a clinical blood-based solid organ transplantation monitoring test. GraftAssureIQ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. OncoTIME enables research on the tumor immune microenvironment.
What is the current price of IMDX stock?
The current stock price of IMDX is 5.72 USD. The price increased by 0.88% in the last trading session.
Does INSIGHT MOLECULAR DIAGNOSTIC pay dividends?
IMDX does not pay a dividend.
How is the ChartMill rating for INSIGHT MOLECULAR DIAGNOSTIC?
IMDX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the market cap for INSIGHT MOLECULAR DIAGNOSTIC?
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) has a market capitalization of 163.94M USD. This makes IMDX a Micro Cap stock.
When does INSIGHT MOLECULAR DIAGNOSTIC (IMDX) report earnings?
INSIGHT MOLECULAR DIAGNOSTIC (IMDX) will report earnings on 2026-03-23, after the market close.
Can you provide the ownership details for IMDX stock?
You can find the ownership structure of INSIGHT MOLECULAR DIAGNOSTIC (IMDX) on the Ownership tab.